Free neuropathology最新文献

筛选
英文 中文
Newton's cradle philosophy and stress relief or what goes up must come down. 牛顿的摇篮哲学和减压理论或者上升的一定会下降。
Free neuropathology Pub Date : 2026-10-21 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-10294
Isidro Ferrer
{"title":"Newton's cradle philosophy and stress relief or what goes up must come down.","authors":"Isidro Ferrer","doi":"10.17879/freeneuropathology-2026-10294","DOIUrl":"https://doi.org/10.17879/freeneuropathology-2026-10294","url":null,"abstract":"","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"26"},"PeriodicalIF":0.0,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13712332/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A neuropathology career nudged along by circumstances. 一个受环境影响的神经病理学事业。
Free neuropathology Pub Date : 2026-10-15 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-10215
Lawrence A Hansen
{"title":"A neuropathology career nudged along by circumstances.","authors":"Lawrence A Hansen","doi":"10.17879/freeneuropathology-2026-10215","DOIUrl":"https://doi.org/10.17879/freeneuropathology-2026-10215","url":null,"abstract":"","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682595/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
70th Annual Meeting of the German Society of Neuropathology and Neuroanatomy (DGNN) - Meeting Abstracts: November 04-07, 2026 Berlin, Germany. 德国神经病理学和神经解剖学学会(DGNN)第70届年会-会议摘要:2026年11月04-07日,德国柏林。
Free neuropathology Pub Date : 2026-10-13 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-10413
{"title":"70th Annual Meeting of the German Society of Neuropathology and Neuroanatomy (DGNN) - Meeting Abstracts: November 04-07, 2026 Berlin, Germany.","authors":"","doi":"10.17879/freeneuropathology-2026-10413","DOIUrl":"https://doi.org/10.17879/freeneuropathology-2026-10413","url":null,"abstract":"<p><p>Sehr geehrte Kolleginnen und Kollegen, zur Neurowoche 2026 begrüßen wir Sie im Namen der Deutschen Gesellschaft für Neuropathologie und Neuroanatomie herzlich. Die Neuropathologie hat ihr diagnostisches und wissenschaftliches Spektrum in den vergangenen Jahren deutlich erweitert. Molekulare Tumorklassifikation, Methylierungsdiagnostik, Hochdurchsatzsequenzierung und digitale, KI-gestützte Analyseverfahren sind heute fester Bestandteil unseres Faches und prägen zunehmend klinische Entscheidungen und wissenschaftliche Entwicklungen. Viele dieser Entwicklungen wurden in enger Zusammenarbeit mit den klinischen Neurofächern aufgebaut und weiterentwickelt. Dies betrifft nicht nur die Neuroonkologie, sondern ebenso neurodegenerative, entzündliche und neuromuskuläre Erkrankungen. Die Neuropathologie bewegt sich dabei an der Schnittstelle zwischen Forschung, Diagnostik und klinischer Anwendung. Der enge Austausch mit Neurologie, Neurochirurgie, Neuroradiologie, Neuropädiatrie und den weiteren neurowissenschaftlichen Disziplinen ist hierfür von zentraler Bedeutung. Gerade deshalb bietet die Neurowoche einen besonderen Rahmen. Sie ermöglicht den fachübergreifenden Austausch und schafft Raum für gemeinsame Diskussionen über neue wissenschaftliche Entwicklungen, diagnostische Konzepte und klinische Herausforderungen. Gerade die interdisziplinäre Zusammenarbeit innerhalb der Neurofächer ist eine wesentliche Voraussetzung, um translationale Entwicklungen in die klinische Anwendung zu überführen. Im neuropathologischen Programm erwarten Sie wissenschaftliche Sitzungen mit aktuellen Entwicklungen aus Diagnostik, translationaler Forschung und experimenteller Neurowissenschaft. Besonders wichtig ist uns dabei auch die Einbindung jüngerer Kolleginnen und Kollegen, die mit neuen wissenschaftlichen und methodischen Impulsen zur Weiterentwicklung unseres Faches beitragen. Wir freuen uns auf die Diskussionen und den persönlichen Austausch während der Neurowoche 2026. Mit besten Grüßen Prof. Dr. Till Acker, Prof. Dr. Christian Mawrin DGNN-Kongresspräsidenten.</p>","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13682542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149240635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A canine brain bank for comparative neuroscience and brain aging research. 用于比较神经科学和脑老化研究的犬类脑库。
Free neuropathology Pub Date : 2026-10-12 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9976
Sarah Darcy, Autumn Beck, Macy Garrood, Andria Slaughter, Alexander Parra, Laura Paredes, Kurt Farrell, John F Crary, Andrew T McKenzie
{"title":"A canine brain bank for comparative neuroscience and brain aging research.","authors":"Sarah Darcy, Autumn Beck, Macy Garrood, Andria Slaughter, Alexander Parra, Laura Paredes, Kurt Farrell, John F Crary, Andrew T McKenzie","doi":"10.17879/freeneuropathology-2026-9976","DOIUrl":"10.17879/freeneuropathology-2026-9976","url":null,"abstract":"<p><p>Companion animal brain banking has been recognized as a valuable approach for translational neuroscience of aging and dementia. However, realizing the full value of canine brain banks depends on optimizing the methods used to collect and preserve the tissue. Whole-brain perfusion-fixation is one promising approach, but it is not yet well described in dogs. Here we describe the development of methods for a canine brain bank (currently n = 55), including whole-brain perfusion-fixation via aortic cannulation and brain extraction. We assessed perfusion quality using gross examination, post-perfusion computed tomography (CT), and histological clearance of blood vessels. We found that body weight and flow rate normalized to body weight were each significantly correlated with perfusion quality in our cohort. To illustrate the kind of analysis the canine brain bank could facilitate, we next performed a preliminary study of brain aging, one of our primary planned research applications. Using a pixel classifier applied to whole-slide images, we quantified lipofuscin burden and found, in this preliminary cohort, that it increased strongly with age in both the thalamus and hippocampus. In the hippocampus, lipofuscin burden was also elevated in dogs with owner-reported cognitive dysfunction, although the current cohort is too small to determine to what extent this association is independent of age. Preliminary electron microscopy studies confirmed that perfusion-fixed tissue from the bank is amenable to ultrastructural analysis. This work describes one approach to canine brain perfusion-fixation and introduces a canine brain tissue resource that may help support future neuroscience research.</p>","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13712238/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease. 现代医学中任何疾病的最高临床试验失败率:淀粉样蛋白靶向和非淀粉样蛋白靶向治疗如何未能改变阿尔茨海默病的病程。
Free neuropathology Pub Date : 2026-08-27 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9650
Michael A S Guth
{"title":"The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease.","authors":"Michael A S Guth","doi":"10.17879/freeneuropathology-2026-9650","DOIUrl":"10.17879/freeneuropathology-2026-9650","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Background:&lt;/b&gt; Alzheimer's disease drug development has produced a 99.6 percent failure rate for disease-modifying compounds (244 compounds tested 2002-2012, one regulatory approval; Cummings et al., 2014; Cummings, 2018)-the most sustained and costly therapeutic failure in the history of modern medicine. The field's standard explanation is that the biology is intractable. The present analysis offers a different and more instructive diagnosis: the failure was not primarily scientific. It was institutional. &lt;b&gt;Objective:&lt;/b&gt; To characterize the structural and institutional forces that sustained investment in repeatedly ineffective mechanisms of action across 567 Phase 2 and Phase 3 Alzheimer's trials from 2010 to 2026, and to determine whether peer-reviewed alternative pathogenic frameworks were available at the time each major Go/No Go decision was made. &lt;b&gt;Methods:&lt;/b&gt; Trials were identified from ClinicalTrials.gov using the following criteria: primary diagnosis of Alzheimer's disease or mild cognitive impairment attributed to Alzheimer's disease; Phase 2 or Phase 3; status of terminated or completed; primary completion date between January 1, 2010 and May 4, 2026. After exclusion of 70 trials not classifiable by mechanism of action, a final analytic dataset of 497 trials was classified by primary mechanism using the Common Alzheimer's Disease Research Ontology (CADRO). A temporal alignment analysis was conducted for the 12 largest trials by enrollment (N ≥ 1,300), mapping each trial's initiation date against the publication dates of peer-reviewed alternative mechanistic frameworks available at the time of trial launch. &lt;b&gt;Results:&lt;/b&gt; Amyloid-targeting approaches accounted for approximately 31 percent of the 497 classified trials, nearly all of which failed to demonstrate clinical efficacy. Among the 12 largest trials, 11 targeted amyloid pathology and 10 were terminated for futility or lack of efficacy. All 12 trials were initiated after the publication in high-impact journals of peer-reviewed alternative frameworks, including the TREM2 neuroinflammation pathway, the antimicrobial protection hypothesis, the periodontitis-associated bacterial pathogenesis hypothesis, and the GLP-1 metabolic pathways. The post-2022 period revealed that genuinely novel non-amyloid mechanisms-TREM2 agonism, GLP-1 receptor stimulation, filamin A modulation, and progranulin/sortilin restoration-also failed to produce clinical benefit at scale despite confirmed target engagement. Three establishment forces are identified as operative causes: regulatory path dependency, institutional entrenchment within grant and editorial review panels, and shareholder-driven sunk-cost pressures. &lt;b&gt;Conclusion:&lt;/b&gt; The 567-trial record constitutes a structural verdict on a model of drug development that was never designed to solve a problem of this complexity. The uniformity of negative results across all mechanism categories-amyloid, tau, neuroinflammation, metabolic, and ","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2026-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532280/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148876755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers. 基于magibu的儿童和青少年中枢神经系统肿瘤模型:与在线DNA甲基化分类器比较的内部表观遗传决策支持框架。
Free neuropathology Pub Date : 2026-08-24 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9648
Gianluca Mattei, Laura Giunti, Mirko Scagnet, Rina Agushi, Federico Mussa, Chiara Caporalini, Iacopo Sardi, Vincenzo Yuto Civale, Alberto Magi, Lorenzo Genitori, Anna Maria Buccoliero
{"title":"A MAGIBU-based model for pediatric and juvenile CNS tumors: an in-house epigenetic decision-support framework compared with online DNA methylation classifiers.","authors":"Gianluca Mattei, Laura Giunti, Mirko Scagnet, Rina Agushi, Federico Mussa, Chiara Caporalini, Iacopo Sardi, Vincenzo Yuto Civale, Alberto Magi, Lorenzo Genitori, Anna Maria Buccoliero","doi":"10.17879/freeneuropathology-2026-9648","DOIUrl":"10.17879/freeneuropathology-2026-9648","url":null,"abstract":"<p><p><b>Background:</b> DNA methylation profiling is a tool that provides key support for central nervous system (CNS) tumor classification. However, diagnostically ambiguous pediatric cases may result in discordant outputs across classifiers. We developed MAGIBU, a cross-platform, projection-based framework that embeds individual methylomes into a fixed CNS reference landscape, ranking diagnostic entities by local epigenetic proximity to support clinician-led integrative diagnosis. <b>Methods:</b> As a proof-of-concept, we evaluated MAGIBU in eight morphologically challenging pediatric/juvenile CNS tumors with unresolved diagnoses after institutional and central pathology review. To establish a benchmark in the absence of a definitive histopathological ground truth, a consensus epigenetic reference was defined a priori for cases showing concordant results between the Heidelberg CNS Tumor Methylation Classifier and Methylscape Analysis. Comparisons were also performed with Epigenomic Digital Pathology (EpiDiP). To validate MAGIBU beyond this discovery cohort, performance was assessed at the family level across the CNS methylation spectrum (n = 678, 28 methylation families), on non-array platforms (whole-genome bisulfite sequencing and Oxford Nanopore), and in a focused analysis of the low-grade glioma and diffuse midline glioma compartment across four independent cohorts (n = 670). <b>Results:</b> In the discovery cohort, MAGIBU achieved high concordance with the consensus reference (Cohen's κ = 0.855), outperforming EpiDiP (κ = 0.278), which frequently placed low-grade tumors in proximity to higher-grade reference regions. <b>Conclusions:</b> MAGIBU provides a stable, quantitative differential diagnosis framework that mitigates the limitations of rigid categorical assignments. By leveraging a distance-based proximity metric, it offers a transparent decision-support tool that integrates effectively with clinical, radiological, and molecular data. While performance is inherently dependent on reference atlas composition, MAGIBU represents a robust complementary approach for the diagnostic workup of ambiguous CNS tumors.</p>","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13532279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148876726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Atypical central neurocytoma with anaplastic histological features in the lateral ventricle of a 37-year-old man. 37岁男性侧脑室非典型中枢神经细胞瘤伴间变性组织学特征。
Free neuropathology Pub Date : 2026-08-17 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9697
Mari Valkonen, Paula Bendel, Tuomas Rauramaa, Susanna Rantala
{"title":"Atypical central neurocytoma with anaplastic histological features in the lateral ventricle of a 37-year-old man.","authors":"Mari Valkonen, Paula Bendel, Tuomas Rauramaa, Susanna Rantala","doi":"10.17879/freeneuropathology-2026-9697","DOIUrl":"https://doi.org/10.17879/freeneuropathology-2026-9697","url":null,"abstract":"<p><p>We report a case of atypical central neurocytoma with anaplastic histological features in the lateral ventricle of a previously healthy 37-year-old man. Histologically, the tumor exhibited anaplastic cell morphology, necrosis, increased mitotic activity, and vascular proliferation. The tumor had copy number alterations, but methylation profiling did not provide a match to any known methylation class, and mutation analyses were negative for pathogenic alterations. Atypical central neurocytoma is a challenging and rare diagnosis, and the World Health Organization (WHO) Classification of Tumors has not yet clarified diagnostic criteria for this putative entity. In a literature review, however, atypical central neurocytoma showed increased aggressiveness compared to conventional central neurocytoma, WHO grade 2.</p>","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13488374/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148801776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurofibrillary tangle distribution in posterior cortical atrophy and typical early-onset Alzheimer's Disease. 后皮质萎缩和典型早发性阿尔茨海默病的神经原纤维缠结分布。
Free neuropathology Pub Date : 2026-07-09 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9686
Denis S Smirnov, Sophie M Dickinson, Melanie F Estrella, Vanessa S Goodwill, Alison J Headley, Donald P Pizzo, Doug Galasko, David P Salmon, Annie Hiniker
{"title":"Neurofibrillary tangle distribution in posterior cortical atrophy and typical early-onset Alzheimer's Disease.","authors":"Denis S Smirnov, Sophie M Dickinson, Melanie F Estrella, Vanessa S Goodwill, Alison J Headley, Donald P Pizzo, Doug Galasko, David P Salmon, Annie Hiniker","doi":"10.17879/freeneuropathology-2026-9686","DOIUrl":"10.17879/freeneuropathology-2026-9686","url":null,"abstract":"<p><p><b>Background and objectives</b>: Posterior Cortical Atrophy (PCA) is a focal variant of Alzheimer's Disease (AD) characterized by disproportionate and early visuospatial deficits with relative sparing of other cognitive abilities. PCA commonly arises before age 65, consistent with early onset AD (EOAD). Because studies of PCA pathology in patients with detailed cognitive assessment are rare, relationships between severity and distribution of neurofibrillary tangle (NFT) density and visuospatial deficits in PCA are not fully known. Our objectives were to: (1) determine if ratio of NFT density in occipital cortex (OC) versus hippocampus (HC) is higher in PCA than typical EOAD and (2) determine if this ratio correlates with severity of visuospatial deficits in EOAD generally. <b>Methods</b>: We determined density of tau NFT pathology in primary visual cortex (OC), midfrontal cortex (MF), and HC and calculated ratios of these densities for EOAD patients with PCA (n = 12) or non-PCA (n = 33) clinical phenotypes. Groups were compared using linear regression that adjusted for age at death and sex. Correlation between NFT density and visuospatial and other cognitive domain scores were examined using linear regression that adjusted for age at cognitive testing, education, sex and test-death interval. Analyses were repeated with the non-PCA EOAD patients grouped into those with mild (EOAD-Typical, n = 21) or severe (EOAD-Visual, n = 12) visuospatial impairment. <b>Results</b>: PCA patients had lower HC (β = -11.7 ± 5.7, p = 0.045) and a trend toward higher OC (β = 6.9 ± 3.7, p = 0.07) NFT density, and higher OC/HC (β = 0.30 ± 0.14, p = 0.04) and OC/MF (β = 0.56 ± 0.16, p = 0.001) ratios, than typical non-PCA EOAD patients. The EOAD-Visual had higher OC/HC NFT ratios (β = 0.38 ± 0.13, p = 0.008) than the EOAD-Typical non-PCA patients even though they did not meet clinical criteria for PCA. Correlations between OC/HC NFT ratios and visuospatial domain scores were strong (β = -1.29 ± 0.45, p = 0.008) and remained significant when limited to the non-PCA EOAD group (β = -1.22 ± 0.43, p = 0.008). <b>Discussion</b>: PCA is associated with a distribution of NFT pathology (i.e., high OC/HC NFT ratio) that coincides with early predominant visuospatial impairment. Non-PCA EOAD with a memory-predominant presentation and concomitant visuospatial impairment has an NFT distribution profile similar to PCA. NFT pathology in occipital cortex may moderate degree of visuospatial impairment in EOAD regardless of clinical syndrome.</p>","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13366614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148450844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neurooncology: 2026 update. 神经肿瘤学:2026年更新。
Free neuropathology Pub Date : 2026-07-09 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9688
Michel Mittelbronn
{"title":"Neurooncology: 2026 update.","authors":"Michel Mittelbronn","doi":"10.17879/freeneuropathology-2026-9688","DOIUrl":"10.17879/freeneuropathology-2026-9688","url":null,"abstract":"<p><p>The present collection of studies highlights major conceptual and translational advances in contemporary neurooncology related to the field of neuropathology. Central themes include the increasing recognition of neuron-tumor interactions, immune microenvironment remodeling, vascular heterogeneity, and epigenetic plasticity as key drivers of brain tumor progression and therapeutic resistance. Glioblastoma emerges as a highly dynamic and synaptically integrated disease entity, while melanoma brain metastases demonstrate profound microglial reprogramming with direct implications for immunotherapy. Novel molecular and spatial profiling approaches further reveal distinct vascular and immune landscapes across gliomas and brain metastases as well as lineage-dependent developmental programs in medulloblastoma. In parallel, rapid advances in artificial intelligence, nanopore sequencing, and real-time molecular diagnostics are reshaping neuropathological workflows and intraoperative decision-making. Proteomic and multi-omics analyses additionally uncover clinically relevant immune-hot glioma subtypes associated with adverse prognosis and spatial immune remodeling. Together, these studies underscore the increasing convergence of molecular neurobiology, immunology, epigenetics, and computational pathology in modern neurooncology and highlight emerging opportunities for precision diagnostics and targeted therapeutic intervention.</p>","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2026-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13359379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Desmoplastic myxoid tumor, SMARCB1-mutant: a case with late recurrence after long-term follow-up. smarcb1突变型黏液样粘连瘤:长期随访后晚期复发1例。
Free neuropathology Pub Date : 2026-07-06 eCollection Date: 2026-01-01 DOI: 10.17879/freeneuropathology-2026-9701
Arnault Tauziède-Espariat, Mathilde Duchesne, Aymeric Rouchaud, Amandine Chabernaud Negrier, Romain Coudert, Joseph Benzakoun, David Guyon, Farah Sassi, Lauren Hasty, Alice Métais, Pascale Varlet
{"title":"Desmoplastic myxoid tumor, SMARCB1-mutant: a case with late recurrence after long-term follow-up.","authors":"Arnault Tauziède-Espariat, Mathilde Duchesne, Aymeric Rouchaud, Amandine Chabernaud Negrier, Romain Coudert, Joseph Benzakoun, David Guyon, Farah Sassi, Lauren Hasty, Alice Métais, Pascale Varlet","doi":"10.17879/freeneuropathology-2026-9701","DOIUrl":"10.17879/freeneuropathology-2026-9701","url":null,"abstract":"","PeriodicalId":73056,"journal":{"name":"Free neuropathology","volume":"7 ","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13359088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书